Parkinson disease psychosis: Update

Behavioural Neurology

Volumn 27, Issue 4, 2013, Pages 469-477

  Friedman, J H ^a  

^a BROWN UNIVERSITY   (United States)

Author keywords

atypical antipsychotic drugs; delusions; hallucinations; neuroleptics; paranoia; Parkinson's disease psychosis; parkinsonism

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; LEVODOPA; MELPERONE; OLANZAPINE; QUETIAPINE; RISPERIDONE; ZIPRASIDONE;

AGRANULOCYTOSIS; ASSOCIATION CORTEX; AUDITORY HALLUCINATION; DELIRIUM; DELUSION; DEMENTIA; DIFFERENTIAL DIAGNOSIS; DIFFUSE LEWY BODY DISEASE; DNA POLYMORPHISM; DRUG TOLERANCE; ELECTROCONVULSIVE THERAPY; EXECUTIVE FUNCTION; HUMAN; LEWY BODY; MENTAL HEALTH; MORTALITY; MOTOR CORTEX; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; MULTICENTER STUDY (TOPIC); ORTHOSTATIC HYPOTENSION; PARASOMNIA; PARIETAL CORTEX; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SLEEP PATTERN; URINARY TRACT INFECTION; VISUAL HALLUCINATION; VISUAL ILLUSION; VIVID DREAM;

ATYPICAL ANTIPSYCHOTIC DRUGS; DELUSIONS; HALLUCINATIONS; NEUROLEPTICS; PARANOIA; PARKINSON'S DISEASE PSYCHOSIS; PARKINSONISM;

ANTIPSYCHOTIC AGENTS; HUMANS; PARKINSON DISEASE; PSYCHOTIC DISORDERS;

EID: 84884237905     PISSN: 09534180     EISSN: 18758584     Source Type: Journal    
DOI: 10.1155/2013/645429     Document Type: Review

References (118)

1. Weintraub D, Burn DJ. Parkinson's disease: The quintessential neuropsychiatric disorder. Move Disord 2011; 26(6): 1022.
2. Kummer A, Teixeira AL. Neuropsychiatry of Parkinson's disease. Arq Neuropsiquaitr 2009; 67(3B): 930.
3. Gallagher DA, Lees AJ, Schrag A.What are the most important non-motor symptoms in patients with Parkinson's disease and are we missing them? Mov Disord 2010; 25(15): 2493.
4. Qin Z, Zhang L, Sun F, Fang X, Meng C, Tanner C, et al. Health related quality of life in early Parkinson's disease: Impact of motor and non-motor symptoms: Results from Chinese levodopa exposed cohort. Park Rel Disord 2009; 15(10): 767.
5. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurol 1993; 43(11): 2227.
6. Aarsland D, Larsen JP, Trandberg E, Laake K. Predictors for nursing home placement in Parkinson's disease: A population-based, prospective study. J Am Geriatr Soc 2000; 48(8): 938.
7. Schrag A, Hovris A, Morley D, Quinn N, Jahanshahi M. Caregiver-burden in parkinson's disease is closely associated with psychiatric symptoms, falls, and disability. Parkinsonism Relat Disord 2006; 12(1): 35.
8. Lee DR, McKeith I, Ghosh-Nodval A, Thomas AJ. Examining carer stress in dementia: the role of sybtype diagnosis and neuropsychiatric symptoms. Int J Geriatr Psychiatry 2012; E pub March 16, doi;10.1002/gps.3799.
9. Ceravolo R, Frosini D, Rossi C, Bonuccelli U. Impulse control disorders in Parkinson's disease: definition, epidemiology, risk factors, neurobiology and management. Park Rel Disord 2009; 15Suppl4: S:111.
10. Voon V, Hassan K, Zurowski M, Duff-Canning S, de Souza M, Fox S, et al. Prospective prevalence of pathologic gambling and medication association in Parkinson' disease. Neurology 2006; 66(11): 1750.
11. Ravina B, Marder K, Fernandez HH, Friedman JH, McDonald W, Murphy D, et al. Diagnostic criteria for psychosis in Parkinson's disease: Report of an NIND, NIMH work group. Mov Disord 2007; 22(8): 1061.
12. Friedman JH. Postencephalitic Parkinsonism, In Stern MB, KollerWC eds. Parkinsonian Syndromes. New York: Marcel Dekker Inc, 1993, p203.
13. Wright WB. Behavioral disorders associated with Artane treatment of post-encephalitic parkinsonism. Confin Neurol 1952: 12(1-2): 45.
14. Poskanzer DC, Schwab RS. Cohort analysis of Parkinson syndrome: Evidence for a single etiology related to subclinical infection about 1920. J Chronic Dis 1963; 16: 961.
15. Fenelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson's disease in the pre-levodopa era. Neurology 2006; 66(1): 93.
16. Aarsland D, Ballard C, Larsen JP,McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int J Geriatr Psychiatry 2001; 16(5): 528.
17. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, et al.: Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 2005; 65(12): 1863.
18. Dotchin CL, Jusabani A, Walker RW. Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania. Park Rel Disord 2009; 15(6): 457.
19. Friedman JH. Managing idiopathic Parkinson's disease in patients with schizophrenic disorders. Park Rel Disord. 2011; 17(3): 198.
20. Friedman JH, Fernandez HH. Autopsy follow up of a patient with schizophrenia and presumed idiopathic Parkinson disease. Clin Neuropharmacol 2001; 24(2): 120.
21. Chou KL,Messing S, Oakes D, Feldman PD,Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin Neuropharmacol 2005; 28(5): 215.
22. Goetz CG. Hallucinations in Parkinson's disease: The clinical syndrome: Adv Neurol 1999; 80: 419.
23. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long-term therapy. Am J Psychiatry 1982; 139(4): 494.
24. Mack J, Rabins P, Anderson K, Goldstein S, Grill S, Hirsch ES, et al. Prevalence of psychotic symptoms in a community based Parkinson disease sample. Am J Ger Psychiatry 2012; 20(2): 123.
25. Fernandez HH, Aarsland D, Fenelon G, Friedman JH, Marsh L, TroesterAL et al. Scales to assess psychosis in Parkinson's disease. Mov Disord 2008; 23(4): 484.
26. Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol 2009; 5(6): 331.
27. Forsaa EB, Larsen JP,Wentzel-Larsen T, Goetz CG, Stebbins GT, Aarsland D, et al. A 12-year population-based study of psychosis in Parkinson's disease. Arch Neurol 2010; 67(14): 996.
28. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J Neurol Neurosurg Psychiatry 2001; 70(6): 734-8. (Pubitemid 32554202)
29. Fenelon G, Alves G. Epidemiology of psychosis in Parkinson's disease. J Neurol Sci 2010; 289(1-2): 12.
30. Postuma RB, Bertrand JA, Montplaisir J, Desjardins C, Vendentte M, Rios Romenets S, et al. Rapid eye movement sleep behavior disorder and risk of dementia in Parkinson's disease: A prospective study. Mov Disord 2012; 27(6): 720.
31. Biglan KM, Holloway RG Jr, McDermott MP, Richard IH. Risk factors for somnolence, edema and hallucinations in early Parkinson disease. Neurology 2007; 69(2): 187.
32. Kiziltan G, Ozekmekci S, Ertain S, Ertain T, Erginoz E, et al. Relationship between age and subtypes of psychotic symptoms in Parkinson's disease. J Neurol 2007; 254(4): 448.
33. Ecker D, Unrath A, Kassubek J, Sabolek K. Dopamine agonists and their risk to induce psychotic episodes in Parkinson's disease: A case control study. BMC Neurol 2009; 9: 23.
34. Grossi D, Trojano L, Pellecchia MT, Amboni M, Gragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry 2005; 20(7): 668.
35. Santangelo G, Trojano L, Vitale C, Iannicielo M, Amboni M, Grossi D, et al. A neuropsychological longitudinal study in Parkinson's disease psychosis. Mov Disord 2007; 22(16): 2418.
36. Barnes J, Boubert L. Executive functions are impaired in patients with Parkinson's disease with visual hallucinations. J Neurol Neurosurg Psychiatry 2008; 79(2): 190.
37. Manganelli F, Vitale C, Santangelo G, Pisciotta C, Iodice R, Cozzolini A, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 2009; 132(Pt9): 235.
38. Arnulf I, Bonnet AM, Damier P, Bejjani P, Seilhean D, Derenne JP, et al. Hallucination, REMsleep, and Parkinson's disease: A medical hypothesis. Neurol 2000; 55(2): 281.
39. Gallagher DA, Parkkinen L,O'Sullivan SS, Spratt A, Shah A, Davey CC, et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 2011; 134(Part11): 3299.
40. Goetz CG, Pappert EJ, Blasucci LM, Stebbins GT, Ling ZD, NoraMV, et al. Intravenous levodopa in hallucinating Parkinson's disease patients: High dose challenge does not precipitate hallucinations. Neurol 1998; 50(2): 515.
41. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002; 125(Pt2): 391.
42. Kalaitzakis ME, Christian LM, Moran LB, Graeber MB, Pearce RK, Gentleman SM. Dementia and visual hallucinations asociated with limbic pathology in Parkinson's disease. Park Rel Disord 2009; 15(3): 196.
43. Papapetropoulos S, McCorquodale DS, Gonzalez J, Jean-Gilles L, Mash DC. Cortical and amygdalar Lewy body burden in Parkinson's disease patientswith visual hallucinations. Park Rel Dis 2005; 12(4): 253-6. (Pubitemid 43737238)
44. Bertram K,Williams DR. Visual hallucinations in the differential diagnosis of parkinsonism. J Neurol, Neurosurg and Psychiatry 2012; 83(4): 448.
45. Factor SA, Steenland K, Higgins DS, Molho ES, Kay DM, Montimurro J, et al. Disease-related and genetic correlates of psychotic symptoms in Parkinson's disease. Mov Dis 2011; 26: 2190.
46. Williams DR, Lees AJ. Visual hallucinations in the diagnosis of idiopathic Parkinson disease: a retrospective autopsy study. Lancet Neurol 2005; 4(10): 605.
47. Meppelink AM, de Jong BM, Renken R, Leenders KL, Cornelissen FW, van Laar T. Impaired visual processing preceding image recognition in Parkinson's disease patient with visual hallucinations. Brain 2009; 132(Pt11): 2980.
48. Kurita A, Murakami M, Takagi S, Matsushima M, Suzuki M. Visual hallucinations and altered visual information processing in Parkinson disease and dementia with Lewy bodies. Mov Disord 2010; 25(2): 167.
49. De Luca V, Annesi G, De Marco EV, de Bartolomeis A, Nicoletti G, Publiese P, et al. HOMER1 promoter analysis in Parkinson's disease: Association sutyd with psychotic symptoms. Neuropsychobiology 2009; 59(4): 239.
50. Boecker H, Ceballow-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations.Arch Neurol 2007; 64(7): 984.
51. Stebbins GT, Goetz CG, Carrillo MC, Bangen KJ, Turner DA, Glover GH, et al. Altered cortical visual processing in Parkinson's disease with hallucinations: an fMRI study. Neurology 2004; 63(8): 1409.
52. Nagahama Y, Okina T, Suzuki N, Matsuda M. Neural correlates of psychotic symptoms in dementia with Lewy bodies. Brain 2010; 13(Pt2): 557.
53. Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, Campdelacreu J, Gascon J, Falcon C, et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov Disord 2010; 25(5): 615.
54. Huot P, Johnston TH, Darr T, Hazrati N, Visanji NP, Pires D, et al. Increased 5HT2A receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Mov Disord 2010; 25(10): 1399.
55. Goetz CG, Fan W, Leurgans S. Antipsychotic treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening. Mov Disord 2008; 23(11): 1541.
56. Goetz CG, Stebbins GT.Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995; 45(4): 669.
57. Parkinson Study Group: Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999; 340(10): 757.
58. Friedman JH. The management of the levodopa psychoses. Clin Neuropharmacol 1991(4); 14: 283.
59. Friedman JH. "Drug holidays" in the treatment of Parkinson's disease. Arch Int Med 1985; 145(5): 913.
60. Scholz E, Dichgans J. Treatment of drug-induced exogenous psychosis in parkinsonism with clozapine and fluperlapine. Eur Arch Psychiatry Neurol Sci 1985; 235(1): 60.
61. Factor SA, Brown D, Molho ES, Podskalny GD: Clozapine: A 2-year open trial in Parkinson's disease patients with psychosis. Neurology 1994; 44(3 Pt 1): 544-6. (Pubitemid 24098159)
62. Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger L, et al. Clozapine use in Parkinson's disease: a retrospective analysis of a large multi-centered clinical experience. Mov Disord 1998; 13(3): 377.
63. Ostergaard K, Dupont E. Clozapine treatment of drug induced psychosis in late stages of Parkinson's disease. Acta Neurol Scand 1988; 78(4): 349.
64. Roberts HE, Dean RC, Stoudemire A. Clozapine treatment of psychosis in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1989; 1(2): 190.
65. Lew MF, Waters CH. Clozapine treatment of parkinsonism with psychosis. J Am Ger Soc 1993; 41(6): 669.
66. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. Adv Neurol 1993; 60: 703-6.
67. Pollak P, Tison F, Rascol O, Destee A, Pere JJ, Senard JM, et al.: Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004; 75(5): 689.
68. Fernandez HH, Friedman JH, Lansang MC, Factor SA,Molho ES, Coskun DJ. Diabetes mellitus among parkinsonian patients treated chronically with clozapine. Park Rel Disord 2004; 10(7): 439.
69. Thomas AA, Friedman JH. Current use of clozapine in Parkinson's disease and related disorders. Clin Neuropharmacol 2010; 33(1): 14.
70. Pakkenberg H, Pakkenberg B. Clozapine in the treatment of tremor. Acta Neurol Scand. 1986; 73(3): 295.
71. Friedman JH, Lannon MC. Clozapine-responsive tremor in Parkinson's disease. Mov Disord 1990; 5(3): 225.
72. Bonuccelli U, Ceravalo R, Salvetti S, D'Avino C, Del Dotto P, Rossi G, et al. Clozapine in Parkinson's disease tremor. Effects of acute and long term administration. Neurol 1997; 49(6): 1587.
73. Jansen EN. Clozapine in the treatment of tremor in Parkinson's disease. Acta Neurol Scand 1994; 89(4): 262-5. (Pubitemid 24159038)
74. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergman PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996; 47(4): 1085.
75. OndoWG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-hallucinations. Mov Disord 2002; 17(5): 1031.
76. Breier A, Sutton VK, Feldman PD, Kaddam DL, Ferchland I, Wright P, et al. Olanzapine in the treatment of dopamimeticinduced psychosis in patient with Parkinson's disease. Biol Psych 2002; 52(5): 438.
77. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 2000; 55(6): 789.
78. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for olanzapine in psychiatrically stable Parkinson's disease patients: results of an open label pilot study. Clin Neuropharmacol 1998; 21(5): 285.
79. Meco G, Alessandria A, Bonifati V, Giustini P. Risperidone for hallucinations in levodopa-treated Parkinson's disease patients. Lancet 1994; 343(8909): 1370.
80. MohrE, Mendis T,Hildebrand K, DeDeyn PP.Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial. Mov Disord 2000; 15(6): 1230-7.
81. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease. Lancet 1994; 344(8923): 681.
82. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995; 56(12): 556.
83. LopezDelVal LJ, Santos S. Quetiapine and ziprasidone in the treatment of the psychotic disorders in Parkinson's disease. Rev Neurol 2004; 39(7): 661.
84. Berkowitz AL. Ziprasidone therapy in elderly patients with psychotic mood disorders and Parkinson's disease. Psychiatry (Edgemont) 2006; 3(11): 59-63.
85. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience. Clin Neuropharmacol 2004; 27(1): 4.
86. Friedman JH, Berman RM, Goetz CG, Factor SA, OndoWG, Wojcieszek J et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease.MovDisord 2006; 21(12): 2078.
87. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006; 21(9): 1538.
88. Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007; 109(2): 188.s
89. Rocha FL, Hara C, Ramos MG, Kascher GG, Santos MA, de Oliveira Lanca G, et al. An exploratory open label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia. Dement Geriatr Cogn Disord 2006; 22(5-6): 445.
90. Workman RH jr, Orengo CA, Bakey AA,Milinari VA, Kunik ME. The use of risperidone for psychosis and agitation in demented patients with Parkinson's disease. J Neuropsych Clin Neurosci 1997; 9(4): 594.
91. Michelli F, Taubenslag N, Gatta E, Scorticati MC. Ziprasidone in pysychosis in Parkinson's disease. Clin Neuropharmacol 2005; 28(5): 254.
92. Duran-Ferreras E, Alvarez-Lopez M, Gartcia-Moreno JM, Chacon J. Ziprasidone in parkinsonian dopamine psychosis. Rev Neurol 2008; 46(8): 476.
93. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone in treatment of psychosis in Parkinson's disease. J Neuropsych Clin Neurosci 2000; 12(3): 364.
94. Pintor L, Valldeoriola F, Bailles E, et al. Ziprasidone versus clozapine in the treatment of psychotic symptoms in Parkinson's disease: A randomized open label clinical trial. Clin Neuropharmacol 2012; 35(2): 61.
95. Morgante L, Epifanio A, Spina E, Zappia M, Di Rosa AE, Marconi R, et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin Neuropharmacol 2004; 27(5): 153.
96. Prohorov T, Klein C, Miniovitz A, Dobvonevsky E, Rabey JM. the effect of quetiapine in psychotic Parkinson patients with and without dementia. An open label study using a structured interview. J Neurol 2006; 253(2): 171.
97. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M. Quetiapine for the treatment of drug induced psychosis in Parkinson's disease. Mov Disord 1999; 14(3): 484.
98. Merims D, Balas M, Peretz C, Shabtai H, Giliadi N. Raterblinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin Neuropharmacol 2006; 29(6): 331.
99. Ondo WG, Tintner R, Vuong KD, Lai D, Ringholz G. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005; 20(8): 958.
100. Rabey JM, Prohorov T, Miniovich A, Klein C. The effect of quetiapine in Parkinson's disease (PD) psychotic patients: A double-blind labeled study of three months duration. Mov Disord 2007; 22(3): 313.
101. Shotbolt P, Samuel M, Fox C, David AS. A randomized controlled trial of quetiapine for psychosis in Parkinson's disease. Neuropsychiatr Dis Treat 2009; 5: 327-32.
102. Fernandez HH, Okun MS, Rodriguez RL, Malaty IA, Romrell J, Sun A, et al. Quetiapine improves visual hallucinations in Parkinson's disease but not through normalization of sleep architecture: Results of a double blind clinicalpolysomnograph study. Int J Neurosci 2009; 119(12): 2196.
103. Barbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct Neurol 1996; 11(4): 201.
104. Friedman JH.Melperone is ineffective in treating Parkinson's disease psychosis. Mov Disord 2012; 27(6): 803.
105. Fabbrini G, Barbanti P,Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol Sci 2002; 23(1): 41.
106. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int J Geriatr Psychiatry 2003; 18(10): 937.
107. Sobow T. Parkinson's disease related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: A case series. Neurol Neurochir Pol 2007; 41(3): 276.
108. Bergman J, Lerner V. Successful use of donepezil for the treatment of psychotic symptoms in patient with Parkinson's disease. Clin Neuropharmacol 2002; 25(3): 107.
109. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of Parkinson psychosis and cognitive impairment: Preliminary findings from an open trial. Mov Disord. 2001; 16(6): 1171.
110. Zoldan J, Friedberg G, Livneh M, Melamed E. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT3 receptor antagonist. Neurology 1995; 45(7): 1305.
111. Eichhorn TE, Brunt E, OertelWH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 1996; 47(6): 1608.
112. Meltzer HY,Mills R, Revell S,Williams H, Johnson A, Bahr D, et al. Pimavanserin, a serotonin (2A) receptor inverse agonist for the treatment of Parkinson's disease psychosis. Neuropsychopharmacol 2010; 35(4): 881.
113. Friedman JH, Ravina B,Mills R, Burn D,Williams H, Revell S, et al. A multi center, placebo controlled, double blind trial to examine the safety and efficacy of pimavanserin in the treatment of psychosis in Parkinson's disease. AAN abstract, Toronto, 2010.
114. Ueda S, Koyama K, Okubo Y. Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 2010; 26(2): 111.
115. Factor SA, Molho ES, Brown DL. Combined clozapine and ECT for the treatment of drug induced psychosis in Parkinson's disease. J Neuropsychiatry and Clin Neurosci 1995; 7(3): 304.
116. Usui C, Hatta K, Doi N, Kubo S, Kamigeichi R, Nakanishi N, et al. Improvements in both psychiatric and motor signs in Parkinson's disease, and changes in cerebral regional blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35(7): 1704.
117. Muralidharam K, Thimmaiah R, Chakraborty V, Jain S. Bifrontal ECT for drug induced psychosis in Parkinson's disease. Ind J Psychiatry 2011; 53(2): 156.
118. Miyasaki JM, Shannon K,Voon V, Ravina B, Kleiner-Fisman G, Anderson K, et al. Practice Parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006; 66(7): 996.